What is PEN's market cap?

$12.71B, based on the Nov 4 close of $322.45.

What is PEN's P/E ratio?

80.9× trailing-twelve-month earnings of $157.02M.

Does Penumbra pay a dividend?

No regular cash dividend has been paid in the last year.

How much of PEN is sold short?

2.3M shares, 5.9% of float, as of Oct 15, 2026.

What sector is PEN in?

Healthcare, in the Surgical Instruments industry.

NYSE · PENHealthcareSurgical Instruments

Penumbra, Inc. (PEN)

$322.45+0.76%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$321.34▲ 42.07% in range

Nov 3, 2025Low $225.54 · High $359.40Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

Penumbra closed at $322.45 on Nov 4, up 0.76%, 10.3% below its 52-week closing high. Volume of 374.3K shares was 0.90× its 20-day average (close to normal).

Split-adjusted performance: +1.7% over one month, -0.5% over six months, +42.6% over one year.

In the quarter ended Sep 30, 2026, revenue was $410.14M, up 15.6% from a year earlier, with a net margin of 10.3%.

Short interest was 2.3M shares at the Oct 15 settlement (5.9% of float, 6.8 days to cover).

Market cap$12.71B39.4M shares

Revenue · quarter$410.1M+15.6% YoY

Diluted EPS$1.07−8.5% YoY

P/E · TTM80.9×P/S 8.1×

Net margin10.3%Gross 68.3%

Dividend yieldNone

52-week range225.54 – 359.40−10.3% from high

Volume374.3K0.90× 20-day avg

Volatility · 60d7.8%Annualised

Short % of float5.9%6.8 days to cover

Net cash$652.2MCash $673.6M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.3%1M +1.7%3M −0.7%6M −0.5%YTD +3.7%1Y +42.6%3Y +68.6%5Y +18.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum53

Revenue growth66

Net margin80

Value (low P/E)13

Size90

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →

Shares short2.3M+0.8% vs prior

Days to cover6.8Settled Oct 15

% of float5.9%

Short vol. 10d43.2%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
PENPenumbra	$322.45	+0.76%	−0.5%	+15.6%	10.3%	80.9	$12.71B
BAXBaxter International	$26.50	+3.96%	+56.1%	+5.0%	9.9%	—	$13.71B	Compare
GMEDGLOBUS MEDICAL	$87.10	+9.45%	−2.4%	+5.9%	19.2%	21.8	$11.69B	Compare
PODDInsulet	$165.02	+6.56%	+9.1%	+23.5%	11.8%	30.5	$11.44B	Compare
GKOSGlaukos	$246.70	+5.86%	+82.4%	+58.0%	1.0%	—	$14.60B	Compare
SOLVSolventum	$89.35	+5.42%	+25.9%	+2.2%	4.2%	10.6	$15.21B	Compare
TFXTeleflex Incorporated	$149.87	+7.09%	+21.6%	+28.9%	17.5%	—	$6.35B	Compare
HAEHaemonetics	$127.42	+5.94%	+141.9%	+5.6%	9.7%	60.2	$5.80B	Compare
WSTWest Pharmaceutical Services	$408.78	+0.44%	+30.8%	+8.7%	24.5%	44.6	$28.48B	Compare

News about Penumbra

All news →

IART vs. PEN: Which Stock Is the Better Value Option?Zacks Investment Research · Oct 1, 2026▼ Negative IART or PEN: Which Is the Better Value Stock Right Now?Zacks Investment Research · Sep 29, 2026▼ Negative Reasons to Retain Penumbra Stock in Your Portfolio for NowZacks Investment Research · Sep 16, 2026Neutral Incuvate Files Patent Infringement Lawsuit Against PenumbraGlobeNewswire Inc. · Aug 25, 2026▼ Negative GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOTGlobeNewswire Inc. · Jul 6, 2026Neutral

Quick answers

What does Penumbra do?: Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians.
What is PEN's market cap?: $12.71B, based on the Nov 4 close of $322.45.
What is PEN's P/E ratio?: 80.9× trailing-twelve-month earnings of $157.02M.
Does Penumbra pay a dividend?: No regular cash dividend has been paid in the last year.
How much of PEN is sold short?: 2.3M shares, 5.9% of float, as of Oct 15, 2026.
What sector is PEN in?: Healthcare, in the Surgical Instruments industry.

About Penumbra

Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

HQ: Alameda, CA4,700 employeesListed Sep 18, 2015penumbrainc.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology